[Efficacy evaluation of polysaccharide nucleic acid-fraction of BCG on vasomotor rhinitis].
OBJECTIVE
To investigate the efficacy and safety of polysaccharide nucleic acid-fraction (BCG-PSN) in the treatment of vasomotor rhinitis.


METHODS
Sixty patients were randomly divided into BCG-PSN group (n = 30) and control group (n = 30). The patients in BCG-PSN group were administered with BCG-PSN 1.0 mg twice a week for two months, and intranasal azelastine was used if needed. The patients in control group were administered with intranasal azelastine solely twice a day, which could be decreased with the symptom relief. Follow-up was 6 months. Symptom and medication scores were recorded. Side effects were registered.


RESULTS
The symptom and medication scores of BCG-PSN group were significantly lower than that of control group (P < 0.01) after BCG-PSN treatment. There was no significant difference in symptom score between the two groups at 6 months after BCG-PSN treatment (P > 0.05), while the medication score of BCG-PSN group was still much lower than that of control group (P < 0.01). No serious adverse events were reported in BCG-PSN group except for local pain on the injection place in one patient.


CONCLUSIONS
BCG-PSN is effective and safe in the treatment of vasomotor rhinitis.
Chen
Jianjun
J
Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. jj-c@tom.com
Kong
Weijia
W
Zhou
Yue
Y
Xiang
Jisheng
J
Shu
Hong
H
Shi
Qiumei
Q
Tan
Huifang
H
D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012223:Rhinitis, Vasomotor / Q000188:drug therapy*; D016037:Single-Blind Method; D055815:Young Adult
D001500:BCG Vaccine